DaVita HealthCare Partners Inc. (NYSE:DVA) has received an average recommendation of “Hold” from the thirteen research firms that are presently covering the firm, MarketBeat Ratings reports. Three analysts have rated the stock with a sell recommendation, seven have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target among analysts that have covered the stock in the last year is $68.67.

Several equities research analysts have commented on DVA shares. TheStreet upgraded DaVita HealthCare Partners from a “c+” rating to a “b-” rating in a research note on Monday, April 3rd. Zacks Investment Research upgraded DaVita HealthCare Partners from a “hold” rating to a “buy” rating and set a $77.00 price objective on the stock in a research note on Tuesday, April 18th. Jefferies Group LLC set a $70.00 price objective on DaVita HealthCare Partners and gave the stock a “buy” rating in a research note on Friday, May 26th. BidaskClub cut DaVita HealthCare Partners from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, Goldman Sachs Group, Inc. (The) reiterated a “sell” rating and set a $62.00 price objective on shares of DaVita HealthCare Partners in a research note on Thursday, May 25th.

In related news, CEO Javier Rodriguez sold 1,294 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The stock was sold at an average price of $66.21, for a total transaction of $85,675.74. Following the transaction, the chief executive officer now directly owns 99,111 shares of the company’s stock, valued at approximately $6,562,139.31. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William L. Roper sold 12,994 shares of the business’s stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $65.89, for a total value of $856,174.66. Following the transaction, the director now directly owns 45,277 shares in the company, valued at $2,983,301.53. The disclosure for this sale can be found here. In the last quarter, insiders have sold 22,702 shares of company stock worth $1,495,492. Company insiders own 2.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. raised its position in DaVita HealthCare Partners by 2.2% in the first quarter. Vanguard Group Inc. now owns 15,080,919 shares of the company’s stock worth $1,025,050,000 after buying an additional 331,482 shares during the last quarter. BlackRock Inc. raised its position in DaVita HealthCare Partners by 2,315.8% in the first quarter. BlackRock Inc. now owns 12,892,477 shares of the company’s stock worth $876,303,000 after buying an additional 12,358,806 shares during the last quarter. State Street Corp raised its position in DaVita HealthCare Partners by 0.5% in the first quarter. State Street Corp now owns 7,533,514 shares of the company’s stock worth $512,049,000 after buying an additional 38,416 shares during the last quarter. Boston Partners raised its position in DaVita HealthCare Partners by 4.2% in the first quarter. Boston Partners now owns 6,812,176 shares of the company’s stock worth $463,024,000 after buying an additional 276,662 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its position in DaVita HealthCare Partners by 11.3% in the first quarter. Bank of New York Mellon Corp now owns 3,129,111 shares of the company’s stock worth $212,686,000 after buying an additional 317,775 shares during the last quarter. 81.92% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY NOTICE: “DaVita HealthCare Partners Inc. (DVA) Receives Consensus Rating of “Hold” from Analysts” was first reported by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of US & international copyright and trademark laws. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/07/11/davita-healthcare-partners-inc-dva-receives-consensus-rating-of-hold-from-analysts.html.

DaVita HealthCare Partners (DVA) traded up 1.64% during trading on Tuesday, reaching $63.36. The company had a trading volume of 1,396,377 shares. The company has a 50 day moving average price of $65.13 and a 200 day moving average price of $66.08. DaVita HealthCare Partners has a 52-week low of $54.50 and a 52-week high of $78.77. The company has a market capitalization of $12.33 billion, a PE ratio of 10.41 and a beta of 0.89.

DaVita HealthCare Partners (NYSE:DVA) last released its earnings results on Tuesday, May 2nd. The company reported $0.79 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.82 by $0.03. The firm had revenue of $3.70 billion during the quarter, compared to the consensus estimate of $3.69 billion. DaVita HealthCare Partners had a net margin of 8.28% and a return on equity of 14.85%. On average, equities analysts forecast that DaVita HealthCare Partners will post $3.52 EPS for the current fiscal year.

About DaVita HealthCare Partners

DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.

Analyst Recommendations for DaVita HealthCare Partners (NYSE:DVA)

Receive News & Ratings for DaVita HealthCare Partners Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita HealthCare Partners Inc. and related companies with MarketBeat.com's FREE daily email newsletter.